Azione ALT ALTIMMUNE, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Altimmune, Inc.

Azioni

ALT

US02155H2004

Mercato chiuso - Nasdaq
Altri mercati azionari
 22:00:00 27/06/2024 		Variaz. 5gg Var. 1 gen.
6,385 USD +2,08% Grafico intraday di Altimmune, Inc. +7,49% -43,24%
26/06 Muore il CFO di Altimmune Richard Eisenstadt MT
23/06 Altimmune, Inc. presenta i dati dello studio di Fase 2 MOMENTUM di pemvidutide nell'obesità all'84esima Sessione Scientifica dell'American Diabetes Association CI

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!
Registrazione 100% gratuita
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
ALT DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important July 5 Deadline in Securities Class Action - ALT
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Altimmune CFO Richard Eisenstadt Dies
Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt
Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer
Contact Levi & Korsinsky by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT)
Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association?s 84th Scientific Sessions
Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association's Scientific Sessions
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione ALT
  4. Notizie Altimmune, Inc.
  5. Altre lingue